{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:39:11Z","timestamp":1778542751344,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2018J01254"],"award-info":[{"award-number":["2018J01254"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2020J011094"],"award-info":[{"award-number":["2020J011094"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","ajicjournal.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Infection Control"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ajic.2024.02.016","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T16:32:36Z","timestamp":1709137956000},"page":"774-784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of novel \u03b2-lactams for Pseudomonas aeruginosa infection: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"52","author":[{"given":"Meijia","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junshan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ajic.2024.02.016_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00355-19","article-title":"The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program","volume":"63","author":"Diekema","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajic.2024.02.016_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41392-022-01056-1","article-title":"Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ajic.2024.02.016_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.07.002","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: mechanisms, epidemiology and evolution","volume":"44","author":"Botelho","year":"2019","journal-title":"Drug Resistance Updates"},{"key":"10.1016\/j.ajic.2024.02.016_bib4","series-title":"Antibiotic Resistance Threats in the United States, 2019","year":"2019"},{"key":"10.1016\/j.ajic.2024.02.016_bib5","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/antibiotics11091212","article-title":"Carbapenem combinations for infections caused by carbapenemase-producing Pseudomonas aeruginosa: experimental in vitro and in vivo analysis","volume":"11","author":"Herrera-Espejo","year":"2022","journal-title":"Antibiotics"},{"issue":"12","key":"10.1016\/j.ajic.2024.02.016_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01858-17","article-title":"Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Supplement_7","key":"10.1016\/j.ajic.2024.02.016_bib7","doi-asserted-by":"crossref","first-page":"S519","DOI":"10.1093\/cid\/ciz823","article-title":"Cefiderocol: a novel siderophore cephalosporin defeating carbapenem-resistant pathogens","volume":"69","author":"Bonomo","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajic.2024.02.016_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13017-017-0141-6","article-title":"The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections","volume":"12","author":"Sartelli","year":"2017","journal-title":"World J Emerg Surg"},{"key":"10.1016\/j.ajic.2024.02.016_bib9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajic.2024.02.016_bib10","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajic.2024.02.016_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/14787210.2018.1429912","article-title":"Novel \u03b2-lactam\/\u03b2-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials","volume":"16","author":"Chen","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ajic.2024.02.016_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.ajic.2024.02.016_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","article-title":"BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses","volume":"19","author":"B\u00e9liveau","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ajic.2024.02.016_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.ajic.2024.02.016_bib15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.ajic.2024.02.016_bib16","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.ajic.2024.02.016_bib17","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ajic.2024.02.016_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.ajic.2024.02.016_bib19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.ajic.2024.02.016_bib20","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ajic.2024.02.016_bib21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.ajic.2024.02.016_bib22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/INF.0000000000002392","article-title":"Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children \u22653 months to <18 years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.ajic.2024.02.016_bib23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ajic.2024.02.016_bib24","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.ajic.2024.02.016_bib25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/INF.0000000000003832","article-title":"Safety and efficacy of ceftolozane\/tazobactam versus meropenem in neonates and children with complicated urinary tract infection, including pyelonephritis: a phase 2, randomized clinical trial","volume":"42","author":"Roilides","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ajic.2024.02.016_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijid.2022.08.003","article-title":"A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane\/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections","volume":"123","author":"Sun","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"7","key":"10.1016\/j.ajic.2024.02.016_bib27","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1128\/AAC.03074-15","article-title":"Characteristics and outcomes of complicated intra-abdominal infections involving Pseudomonas aeruginosa from a randomized, double-blind, phase 3 ceftolozane-tazobactam study","volume":"60","author":"Miller","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.ajic.2024.02.016_bib28","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.ajic.2024.02.016_bib29","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"9981","key":"10.1016\/j.ajic.2024.02.016_bib30","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ajic.2024.02.016_bib31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ajic.2024.02.016_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.drup.2015.08.002","article-title":"The increasing threat of Pseudomonas aeruginosa high-risk clones","volume":"21-22","author":"Oliver","year":"2015","journal-title":"Drug Resistance Updates"},{"issue":"7","key":"10.1016\/j.ajic.2024.02.016_bib33","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40265-019-01112-1","article-title":"New drugs for multidrug-resistant gram-negative organisms: time for stewardship","volume":"79","author":"Jean","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ajic.2024.02.016_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/14787210.2023.2166931","article-title":"The efficacy and safety of ceftolozane-tazobactam in the treatment of GNB infections: a systematic review and meta-analysis of clinical studies","volume":"21","author":"Chi","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"8","key":"10.1016\/j.ajic.2024.02.016_bib35","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/jac\/dky124","article-title":"Efficacy and safety of ceftazidime\/avibactam: a systematic review and meta-analysis","volume":"73","author":"Sternbach","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.ajic.2024.02.016_bib36","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ijantimicag.2018.07.004","article-title":"Evaluation of the efficacy and safety of ceftazidime\/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis","volume":"52","author":"Zhong","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.ajic.2024.02.016_bib37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijantimicag.2019.09.007","article-title":"Ceftazidime\/avibactam versus carbapenems for the treatment of infections caused by Enterobacteriaceae: a meta-analysis of randomised controlled trials","volume":"54","author":"Che","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10.1016\/j.ajic.2024.02.016_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02569-17","article-title":"In vitro activity of ceftazidime-avibactam against clinical isolates of enterobacteriaceae and pseudomonas aeruginosa collected in Asia-pacific countries: results from the INFORM global surveillance program, 2012 to 2015","volume":"62","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ajic.2024.02.016_bib39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2018.04.012","volume":"92","author":"Sader","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 7","key":"10.1016\/j.ajic.2024.02.016_bib40","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.ajic.2024.02.016_bib41","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ajic.2024.02.016_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.614058","article-title":"Mobile carbapenemase genes in Pseudomonas aeruginosa","volume":"12","author":"Yoon","year":"2021","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.ajic.2024.02.016_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.01026-20","article-title":"Ceftolozane\/tazobactam resistance and mechanisms in carbapenem-nonsusceptible Pseudomonas aeruginosa","volume":"6","author":"Teo","year":"2021","journal-title":"MSphere"},{"issue":"7","key":"10.1016\/j.ajic.2024.02.016_bib44","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/phar.1609","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"35","author":"Cho","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.ajic.2024.02.016_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02603-21","article-title":"Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant enterobacterales bloodstream infection: a systematic review and meta-analysis","volume":"10","author":"Chen","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"7","key":"10.1016\/j.ajic.2024.02.016_bib46","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/cid\/ciab757","article-title":"Cefiderocol: a new cephalosporin stratagem against multidrug-resistant gram-negative bacteria","volume":"74","author":"Ong\u2019Uti","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ajic.2024.02.016_bib47","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.ajic.2024.02.016_bib48","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1128\/AAC.00843-15","article-title":"Activity of meropenem combined with RPX7009, a novel \u03b2-lactamase inhibitor, against gram-negative clinical isolates in New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.ajic.2024.02.016_bib49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10096-021-04363-7","article-title":"Comparative activity of newer \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020","volume":"41","author":"Sader","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.ajic.2024.02.016_bib50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1017\/ice.2021.394","article-title":"Regional outbreak of multidrug-resistant Klebsiella pneumoniae carbapenemase-producing Pseudomonas aeruginosa","volume":"44","author":"Tadese","year":"2023","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"10.1016\/j.ajic.2024.02.016_bib51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cmi.2021.07.018","article-title":"In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection","volume":"28","author":"Candel","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ajic.2024.02.016_bib52","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3390\/ph15040463","article-title":"Microbiological, clinical, and PK\/PD features of the new anti-gram-negative antibiotics: \u03b2-lactam\/\u03b2-lactamase inhibitors in combination and cefiderocol: an all-inclusive guide for clinicians","volume":"15","author":"Principe","year":"2022","journal-title":"Pharmaceuticals"}],"container-title":["American Journal of Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196655324001044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196655324001044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:40:47Z","timestamp":1718844047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196655324001044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0196655324001044"],"URL":"https:\/\/doi.org\/10.1016\/j.ajic.2024.02.016","relation":{},"ISSN":["0196-6553"],"issn-type":[{"value":"0196-6553","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of novel \u03b2-lactams for Pseudomonas aeruginosa infection: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Infection Control","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajic.2024.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc.","name":"copyright","label":"Copyright"}]}}